Zero Emission Day is a global initiative that raises awareness about the impact of human activities on climate change and promotes sustainable practices. 

September is a month dedicated to raising awareness about Primary Biliary Cholangitis, I find myself reflecting on the challenges faced by those living with rare cholestatic disease. PBC Awareness Day on September 10th is not just a date on the calendar; it’s a reminder that understanding and suppor

At Ipsen, our commitment to supporting para-athletes is a direct reflection of our core values. We believe in removing barriers and fostering an environment where diversity is celebrated, and every individual is supported to drive innovation. Our company culture encourages all employees to reach the

It was only at 46 years old that Stephen was diagnosed with neuroendocrine cancer. Lovingly married to his wife and father to two sons freshly out of high school, in the prime of life with decades ahead of him, Stephen was shocked and confused by his diagnosis. His doctor told him he had 10 to 15 ye

“We’re often asked, what is the PBC journey? And the challenge is that, well, the PBC journey doesn’t exist. There are thousands and thousands of patients around the world, and each of them have an individual journey.” 

At Ipsen, our strategy is anchored in the principle of taking calculated risks to drive innovation. We inspire our employees to embrace innovation and approach risk-taking with a strategic mindset, ensuring that it aligns with our company’s objectives and ethical guidelines.

At Ipsen, our commitment to supporting para-athletes is deeply aligned with our core values of cultivating and embracing diversity. By standing alongside these incredible athletes, we demonstrate our dedication to fostering an inclusive environment where every individual is valued and encouraged to

The first six months of 2024 saw excellent sales growth of 9.5% at CER, and a core operating margin of 32.4%. In light of these strong results, we raised our 2024 total-sales guidance to over 7% growth, with a core operating margin of over 30%.

During the European Association for the Study of the Liver (EASL) congress, leading liver experts, Dr Mark Swain, Dr Emma Culver, and Dr Marco Carbone, sat down to discuss the effective management of primary biliary cholangitis (PBC)

The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.